Elevation Oncology Inc at Oppenheimer Healthcare Conference (Virtual) Transcript
Great. Good morning, everyone. Welcome to Oppenheimer's 33rd Healthcare Conference. Joining me today is Elevation Oncology's Interim CEO and Chief Financial Officer, Joseph Ferra. Just a quick overview, Elevation is a biotech company currently transitioning to development of EO-3021, an anti-Claudin 18.2 ADC.
You may remember that they previously were working on an anti-HER3 NRG1 fusion asset, which they brought to Phase 2 development, and they're currently seeking another partner for developing this asset. If it's okay with you, I'd like to hand it over to you, Joseph.
Sure. Great. Thank you very much, Alex, and thank you to the entire Oppenheimer team for hosting us today. Good morning, everyone. As Alex said, I'm Joseph Ferra, Interim Chief Executive Officer and CFO of Elevation Oncology. I look forward to telling you more about our company today and our highlight of making it -- highlight out of our focus on making a difference for
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |